PL3470400T3 - Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania - Google Patents
Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywaniaInfo
- Publication number
- PL3470400T3 PL3470400T3 PL17812728.8T PL17812728T PL3470400T3 PL 3470400 T3 PL3470400 T3 PL 3470400T3 PL 17812728 T PL17812728 T PL 17812728T PL 3470400 T3 PL3470400 T3 PL 3470400T3
- Authority
- PL
- Poland
- Prior art keywords
- ozanimod
- processes
- preparation
- crystalline forms
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610416179 | 2016-06-14 | ||
| CN201610493910 | 2016-06-29 | ||
| PCT/CN2017/088314 WO2017215617A1 (zh) | 2016-06-14 | 2017-06-14 | 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3470400T3 true PL3470400T3 (pl) | 2025-08-04 |
Family
ID=60663299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17812728.8T PL3470400T3 (pl) | 2016-06-14 | 2017-06-14 | Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11111223B2 (pl) |
| EP (2) | EP3470400B1 (pl) |
| CN (2) | CN114957157A (pl) |
| DK (1) | DK3470400T5 (pl) |
| ES (1) | ES3022204T3 (pl) |
| FI (1) | FI3470400T3 (pl) |
| HR (1) | HRP20250558T1 (pl) |
| HU (1) | HUE072197T2 (pl) |
| LT (1) | LT3470400T (pl) |
| PL (1) | PL3470400T3 (pl) |
| PT (1) | PT3470400T (pl) |
| RS (1) | RS66905B1 (pl) |
| SI (1) | SI3470400T1 (pl) |
| SM (1) | SMT202500228T1 (pl) |
| WO (1) | WO2017215617A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3022204T3 (en) | 2016-06-14 | 2025-05-28 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| US11028060B2 (en) | 2016-08-19 | 2021-06-08 | Receptos Llc | Crystalline forms of ozanimod and processes for preparation thereof |
| WO2018050091A1 (zh) | 2016-09-14 | 2018-03-22 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| MA48798B1 (fr) * | 2017-05-22 | 2023-10-31 | Egyt Gyogyszervegyeszeti Gyar | Procédé de production d'ozanimod |
| CN109280035B (zh) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | 奥扎莫德的多晶型及其制备方法 |
| EP3677575A4 (en) | 2017-08-31 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR |
| CN107840830A (zh) * | 2017-09-20 | 2018-03-27 | 广东东阳光药业有限公司 | 盐酸奥扎莫德无水晶型i |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| WO2020152718A1 (en) * | 2019-01-25 | 2020-07-30 | Mylan Laboratories Limited | Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile |
| EP3999495A1 (en) | 2019-07-16 | 2022-05-25 | Synthon B.V. | Improved process for preparing ozanimod |
| EP4126826A1 (en) * | 2020-04-02 | 2023-02-08 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2291080T3 (pl) | 2008-05-14 | 2015-12-31 | Scripps Research Inst | Nowe modulatory receptorów sfingozyno-1-fosforanu |
| DK2913326T3 (da) | 2008-05-14 | 2020-08-17 | Scripps Research Inst | Hidtil ukendte modulatorer af sphingosinphosphatreceptorer |
| CA2780772C (en) * | 2009-11-13 | 2018-01-16 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| EP3062792A1 (en) | 2013-11-01 | 2016-09-07 | Celgene International II Sarl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| CA2981743A1 (en) * | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| ES3022204T3 (en) | 2016-06-14 | 2025-05-28 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| US11028060B2 (en) | 2016-08-19 | 2021-06-08 | Receptos Llc | Crystalline forms of ozanimod and processes for preparation thereof |
| WO2018050091A1 (zh) | 2016-09-14 | 2018-03-22 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| CN108137516A (zh) | 2016-09-14 | 2018-06-08 | 杭州领业医药科技有限公司 | 奥扎莫德的晶型、其制备方法及药物组合物 |
| US20200031784A1 (en) * | 2017-04-07 | 2020-01-30 | Solipharma Llc | Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses |
| EP3677575A4 (en) | 2017-08-31 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR |
| CN107840830A (zh) | 2017-09-20 | 2018-03-27 | 广东东阳光药业有限公司 | 盐酸奥扎莫德无水晶型i |
-
2017
- 2017-06-14 ES ES17812728T patent/ES3022204T3/es active Active
- 2017-06-14 US US16/310,328 patent/US11111223B2/en active Active
- 2017-06-14 EP EP17812728.8A patent/EP3470400B1/en active Active
- 2017-06-14 HU HUE17812728A patent/HUE072197T2/hu unknown
- 2017-06-14 EP EP25155520.7A patent/EP4566676A3/en active Pending
- 2017-06-14 HR HRP20250558TT patent/HRP20250558T1/hr unknown
- 2017-06-14 FI FIEP17812728.8T patent/FI3470400T3/fi active
- 2017-06-14 PL PL17812728.8T patent/PL3470400T3/pl unknown
- 2017-06-14 PT PT178127288T patent/PT3470400T/pt unknown
- 2017-06-14 SI SI201731601T patent/SI3470400T1/sl unknown
- 2017-06-14 CN CN202210226424.4A patent/CN114957157A/zh active Pending
- 2017-06-14 SM SM20250228T patent/SMT202500228T1/it unknown
- 2017-06-14 DK DK17812728.8T patent/DK3470400T5/da active
- 2017-06-14 CN CN201780029499.0A patent/CN109219597A/zh active Pending
- 2017-06-14 WO PCT/CN2017/088314 patent/WO2017215617A1/zh not_active Ceased
- 2017-06-14 LT LTEPPCT/CN2017/088314T patent/LT3470400T/lt unknown
- 2017-06-14 RS RS20250520A patent/RS66905B1/sr unknown
-
2020
- 2020-01-21 US US16/748,303 patent/US11680050B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3470400T (pt) | 2025-04-29 |
| HUE072197T2 (hu) | 2025-10-28 |
| CN109219597A (zh) | 2019-01-15 |
| CN114957157A (zh) | 2022-08-30 |
| HRP20250558T1 (hr) | 2025-07-04 |
| DK3470400T3 (da) | 2025-06-16 |
| SMT202500228T1 (it) | 2025-07-22 |
| FI3470400T3 (fi) | 2025-06-13 |
| US20190337908A1 (en) | 2019-11-07 |
| LT3470400T (lt) | 2025-07-10 |
| EP3470400B1 (en) | 2025-04-02 |
| RS66905B1 (sr) | 2025-07-31 |
| WO2017215617A1 (zh) | 2017-12-21 |
| ES3022204T3 (en) | 2025-05-28 |
| EP3470400A1 (en) | 2019-04-17 |
| EP4566676A3 (en) | 2025-11-05 |
| US20200157065A1 (en) | 2020-05-21 |
| DK3470400T5 (da) | 2025-06-30 |
| EP4566676A2 (en) | 2025-06-11 |
| US11680050B2 (en) | 2023-06-20 |
| SI3470400T1 (sl) | 2025-09-30 |
| US11111223B2 (en) | 2021-09-07 |
| EP3470400A4 (en) | 2019-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3470400T (lt) | Ozanimodo ir ozanimodo hidrochlorido kristalinės formos ir jų gamybos būdo procesai | |
| IL257442A (en) | Process for preparing parp inhibitor, crystalline forms and their uses | |
| IL283480A (en) | Solid forms of lometaferon and lometaferon salts and processes for preparing lometaferon | |
| IL261414B (en) | Solid state forms of venetoclax and processes for preparation of venetoclax | |
| ZA201708417B (en) | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine | |
| IL255738A (en) | A new crystalline form of lenbatinib mesylate and a process for its preparation | |
| PT3580219T (pt) | Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam | |
| IL253360A0 (en) | New crystalline forms of neratinib malate and a process for their preparation | |
| EP3508481A4 (en) | CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME | |
| PT3218351T (pt) | Um método para a preparação, isolamento e purificação de formas farmaceuticamente aplicáveis de ahu-377 | |
| IL272559A (en) | A method for the preparation of 4-(heptafluoro-2-propyl) aniline | |
| PL3529236T4 (pl) | Krystaliczne formy erawacykliny | |
| ZA201702350B (en) | Preparation method for revaprazan hydrochloride | |
| SI3327012T1 (sl) | Kristalinične oblike bilastina in postopki za pripravo le-teh | |
| ZA202004349B (en) | Fluoralkenyl compounds, process for preparation and use thereof | |
| ZA201903950B (en) | Method for the manufacture of efavirenz | |
| PL3216791T3 (pl) | Substancja polimorficzna chlorowodorku jonkenafilu, sposób jej wytwarzania oraz jej kompozycja i zastosowanie | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| IL246835A0 (en) | Improved process for the preparation of trazodone and its hydrochloride salt | |
| GB2559718B (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
| EP3294703A4 (en) | A process for the preparation of verapamil hydrochloride | |
| HUP1500647A2 (en) | Intermediate of baricitinib and process for its preparation | |
| EP3212611A4 (en) | Crystal forms of verapamil hydrochloride | |
| EP3523307A4 (en) | METHOD FOR PRODUCING DORAOLZMID HYDROCHLORIDE | |
| IL253830A0 (en) | A process for the preparation of piperidine-4-carbothioamide hydrochloride |